US Patent Issued to AstraZeneca on July 28 for "Therapeutic combinations of acalabrutinib and capivasertib to treat B-cell malignancies" (Massachusetts Inventors)

ALEXANDRIA, Va., July 28 -- United States Patent no. 12,691,113, issued on July 28, was assigned to AstraZeneca AB (Sodertalje, Sweden).

"Therapeutic combinations of acalabrutinib and capivasertib to treat B-cell malignancies" was invented by Hannah Dry (Waltham, Mass.), Brandon Willis (Waltham, Mass.), Andrew Bloecher (Waltham, Mass.) and Jerome Mettetal (Waltham, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to therapeutic combinations of acalabrutinib and capivasertib, or pharmaceutically acceptable salts thereof, for treating, preventing, partially alleviating, or ameliorating a B-cell malignancy, such as non-Hodgkin's lymphoma, in a subject in need thereof. The pres...